HBV Flare Associated with Immunosuppressive Treatments: It is Still Dangerous in the Third-Generation Antivirals Era
Antiviral Therapy · 2020-04 · 25 (3) · 121-129
DOI: 10.3851/imp3356 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antiviral Therapy, online erschienen am 01.04.2019. Verfasst von Bilal Toka und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, University of Medical Sciences, Konya Education and Research Hospital, Konya, Turkey. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Background
There are limited data about the mortality and morbidity of patients with HBV flare related to immunosuppressive treatments (IST) in the third-generation antivirals era. Herein, we performed a multi-centric study in patients treated with entecavir (ETV) or tenofovir disoproxil fumarate (TDF) and evaluated their clinical course.
Methods
The study group included patients who were referred to gastroenterology or infectious disease specialists at eight different hospitals in Turkey. HBV flare was defined as at least a threefold elevation in alanine aminotransferase (ALT) levels above the upper limit of normal range. The demographic data, IST protocol, virological markers, liver tests, international normalized ratio (INR), HBV DNA, reactivation risk profile according to AGA guideline, MELD and MELD-Na scores were retrospectively evaluated. The primary aim of the study was to determine the liver-related mortality, including transplantation, at 12 weeks and factors predicting it. Secondary aims were to compare ETV and TDF with respect to mortality and time to ALT, bilirubin normalization and HBV DNA undetectability.
Results
The study group included 40 patients (29 males, mean age: 57 ±12 years). Twenty-five patients (62.5%) had a high risk of reactivation. Twenty-six patients received TDF and 14 patients received ETV treatment. Eight (20%) patients developed acute liver failure and one patient (2.5%) underwent living donor liver transplantation. Seven patients died due to liver-related complications, revealing a mortality rate of 17.5%. In multivariate analysis, total bilirubin levels at the onset, ALT levels and delta-MELD score at the first week were the independent risk factors for liver related mortality (HR: 1.222, 1.003, 1.253 and 95% CI: 1.096, 1.362; 1.001, 1.004 and 1.065, 1.470, respectively). There was no significant difference between the TDF and ETV groups with respect to time to normalize ALT and bilirubin levels, HBV DNA undetectability and mortality rates (16% and 21.4%, respectively).
Conclusions
HBV flare associated with IST has a high mortality in the third-generation antivirals era. High total bilirubin at the onset and high ALT and delta-MELD score at the first week predict poor prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, University of Medical Sciences, Konya Education and Research Hospital, Konya, Turkey.
- Department of Gastroenterology, University Faculty of Medicine, Sakarya, Turkey.
- Department of Infectious Diseases and Clinical Microbiology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey.
- Department of Gastroenterology, Cumhuriyet University Faculty of Medicine, Sivas, Turkey.
- Department of Gastroenterology, Çukurova University Faculty of Medicine, Adana, Turkey.
- Department of Gastroenterology, Hitit University Faculty of Medicine, Çorum, Turkey.
Zitieren
APA
Toka, B., Koksal, A. S., İskender, G., Çakmak, E., Üsküdar, O., Sezikli, M., Şirin, G., Yildirim, A. E., Fidan, S., Acar, Ş., Eminler, A. T., Uslan, M. I., & Hülagü, S. (2020). HBV Flare Associated with Immunosuppressive Treatments: It is Still Dangerous in the Third-Generation Antivirals Era. Antiviral Therapy, 25(3), 121-129. https://doi.org/10.3851/imp3356
Vancouver
Toka B, Koksal AS, İskender G, Çakmak E, Üsküdar O, Sezikli M, et al. HBV Flare Associated with Immunosuppressive Treatments: It is Still Dangerous in the Third-Generation Antivirals Era. Antiviral Therapy. 2020;25(3):121-129. doi:10.3851/imp3356
BibTeX
@article{Toka2020,
author = {Toka, Bilal and Koksal, Aydin Seref and İskender, Gülşen and Çakmak, Erol and Üsküdar, Oğuz and Sezikli, Mesut and Şirin, Göktuğ and Yildirim, Abdullah Emre and Fidan, Sami and Acar, Şencan and Eminler, Ahmet Tarik and Uslan, Mustafa Ihsan and Hülagü, Sadettin},
title = {HBV Flare Associated with Immunosuppressive Treatments: It is Still Dangerous in the Third-Generation Antivirals Era},
journal = {Antiviral Therapy},
year = {2020},
volume = {25},
number = {3},
pages = {121--129},
doi = {10.3851/imp3356}
}
EUVIMED